• Luiz Carlos Figueiredo Filho Universidade do Estado do Pará (UEPA)
  • Maria Fernanda de Almeida Cavalcante Aranha Universidade do Estado do Pará (UEPA)
  • Rafael Augusto Silva Cabeça Universidade do Estado do Pará (UEPA)
  • Ricardo Ormanes Massoud Universidade do Estado do Pará (UEPA)
  • Sarah Brazão Cohen University of Central Florida (UCF)
  • Luanna de Melo Pereira Fernandes Universidade do Estado do Pará (UEPA)
  • Rita de Cássia Silva de Oliveira Universidade do Estado do Pará (UEPA)
  • Patrícia Brazão Cohen Universidade do Estado do Pará (UEPA)




Cerebrospinal Fluid, Central Nervous System, Diagnosis, Prognosis, Neurodegenerative Diseases


Introduction: Cerebrospinal fluid (CSF) analysis is critical in the diagnosis, prognosis, and treatment of a wide range of diseases, including multiple sclerosis, encephalitis, meningitis, brain tumors, Creutzfeldt-Jakob disease, Alzheimer's disease, and other neurodegenerative conditions. Objective: Bibliometric analysis of the 100 most cited articles to obtain deeper insights into the status of research in this sector, in order to provide support for evidence-based medicine (EBM). Methodology: The main collection of the Web of Science was used to collect relevant studies on the topic, and the VOSviewer software was employed to build bibliometric networks. The examination did not include materials from editorials, books, patents, or research with unspecified designs. The articles chosen are in the time range from 1991 to 2020. Results: It was noted that most of the articles were human observational studies focusing on the diagnosis of neurodegenerative diseases, specifically Alzheimer's, which were published in neurology and/or Alzheimer's-related journals, mainly in the United States of America. We discovered forward-looking research hotspots and trends in this domain, which can serve as an important guide to neurological research, generating subsidies for medical decision-making. Conclusion: The number of primary articles on the subject points to the need for further future research on CSF associated, mainly, with other neurodegenerative diseases, in addition to Alzheimer's, sustaining the diagnostic efficacy and EBM.


ABDELNOUR, C. et al. Alzheimer’s disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. Movement Disorders, [s. l.], v. 31, n. 8, p. 1203–1208, 2016.

ABDO, W. F. et al. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson’s disease. Movement Disorders, [s. l.], v. 19, n. 5, p. 571–579, 2004.

ALCOLEA, D. et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. NEUROLOGY, [s. l.], v. 85, n. 7, p. 626–633, 2015.

AL-DIWANI, A. et al. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. LANCET PSYCHIATRY, [s. l.], v. 6, n. 3, p. 235–246, 2019.

ALVES, G. et al. CSF A beta(42) predicts early-onset dementia in Parkinson disease. NEUROLOGY, [s. l.], v. 82, n. 20, p. 1784–1790, 2014.

ANDERSEN, A. D. et al. Cerebrospinal fluid biomarkers for Parkinson’s disease - a systematic review. ACTA NEUROLOGICA SCANDINAVICA, [s. l.], v. 135, n. 1, p. 34–56, 2017.

BAICHURINA, I. et al. The Study of Cerebrospinal Fluid microRNAs in Spinal Cord Injury and Neurodegenerative Diseases: Methodological Problems and Possible Solutions. International Journal of Molecular Sciences, [s. l.], v. 23, n. 1, p. 114, 2021.

BALDIOTTI, A. L. P. et al. The Top 100 Most-Cited Papers in Cariology: A Bibliometric Analysis. Caries Research, [s. l.], v. 55, n. 1, p. 32–40, 2021.

BATISTA, L. F.; BARBOSA, S. M.; DIAS, F. M. Meningite bacteriana: uma revisão. Arquivos de Ciências da Saúde da UNIPAR, Umuarama, v. 26, n. 2, p. 135–145, 2022.

BERGER, J. R. Neurosyphilis in Human Immunodeficiency Virus Type 1-Seropositive Individuals. Archives of Neurology, [s. l.], v. 48, n. 7, p. 700, 1991.

BRAND, D. A. et al. Yield of diagnostic testing in infants who have had an apparent life-threatening event. PEDIATRICS, [s. l.], v. 115, n. 4, p. 885–893, 2005.

BRINKMALM, G. et al. A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer’s Disease. PROTEOMICS CLINICAL APPLICATIONS, [s. l.], v. 12, n. 1, 2018.

BRINKMALM, A. et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease. MOLECULAR NEURODEGENERATION, [s. l.], v. 9, 2014.

CAI, M. et al. The past, present, and future of research on neuroinflammation-induced mild cognitive impairment: A bibliometric analysis. [S. l.]: Frontiers Media S.A., 2022.

CHIASSERINI, D. et al. Differential role of CSF fatty acid binding protein 3, alpha-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia. ALZHEIMERS RESEARCH & THERAPY, [s. l.], v. 9, 2017.

COUNTS, S. E. et al. Biomarkers for the Early Detection and Progression of Alzheimer’s Disease. NEUROTHERAPEUTICS, [s. l.], v. 14, n. 1, p. 35–53, 2017.

CRAIG-SCHAPIRO, R. et al. Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer’s Disease Diagnosis and Prognosis. PLOS ONE, [s. l.], v. 6, n. 4, 2011.

CZARNIAK, N. et al. Cerebrospinal Fluid–Basic Concepts Review. [S. l.]: MDPI, 2023.

DAVIS, J. L. Ocular syphilis. CURRENT OPINION IN OPHTHALMOLOGY, [s. l.], v. 25, n. 6, p. 513–518, 2014.

DE SOUZA, L. C. et al. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer’s disease from other cortical dementias. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, [s. l.], v. 82, n. 3, p. 240–246, 2011a.

DE SOUZA, L. C. et al. Similar amyloid-beta burden in posterior cortical atrophy and Alzheimer’s disease. BRAIN, [s. l.], v. 134, p. 2036–2043, 2011b.

DONOVAN, J. et al. Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study. LANCET INFECTIOUS DISEASES, [s. l.], v. 20, n. 3, p. 299–307, 2020.

ECKERSTROM, C. et al. A Combination of Neuropsychological, Neuroimaging, and Cerebrospinal Fluid Markers Predicts Conversion from Mild Cognitive Impairment to Dementia. JOURNAL OF ALZHEIMERS DISEASE, [s. l.], v. 36, n. 3, p. 421–431, 2013.

FERREIRA, D. et al. Meta-review of CSF core biomarkers in Alzheimer’s disease: the state-of-the-art after the new revised diagnostic criteria. FRONTIERS IN AGING NEUROSCIENCE, [s. l.], v. 6, 2014.

FORGRAVE, L. M. et al. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. ALZHEIMER’S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, [s. l.], v. 11, n. 1, p. 730–743, 2019.

FREILICH, R. J.; KROL, G.; DEANGELIS, L. M. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Annals of Neurology, [s. l.], v. 38, n. 1, p. 51–57, 1995.

GADOTH, A. et al. Expanded Phenotypes and Outcomes among 256 LGI1/CASPR2-IgG-Positive Patients. ANNALS OF NEUROLOGY, [s. l.], v. 82, n. 1, p. 79–92, 2017.

GALLUZZI, S. et al. Clinical and biomarker profiling of prodromal Alzheimer’s disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a ‘European ADNI study’. Journal of Internal Medicine, [s. l.], v. 279, n. 6, p. 576–591, 2016.

GANDINI, G. et al. Fibrocartilaginous embolism in 75 dogs: clinical findings and factors influencing the recovery rate. JOURNAL OF SMALL ANIMAL PRACTICE, [s. l.], v. 44, n. 2, p. 76–80, 2003.

GUO, Y. et al. Trends and Developments in the Detection of Pathogens in Central Nervous System Infections: A Bibliometric Study. Frontiers in Cellular and Infection Microbiology, [s. l.], v. 12, 2022.

HALL, S. et al. Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. ARCHIVES OF NEUROLOGY, [s. l.], v. 69, n. 11, p. 1445–1452, 2012.

HAMPEL, H. et al. Alzheimer’s disease biomarker‐guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ 1–42 , total‐tau, phosphorylated‐tau, NFL, neurogranin, and YKL‐40. Alzheimer’s & Dementia, [s. l.], v. 14, n. 4, p. 492–501, 2018.

HEBEL, R.; DUBANIEWICZ-WYBIERALSKA, M.; DUBANIEWICZ, A. Overview of neurosarcoidosis: recent advances. JOURNAL OF NEUROLOGY, [s. l.], v. 262, n. 2, p. 258–267, 2015.

HEPNAR, D. et al. Recommendations for cerebrospinal fluid analysis. [S. l.]: Springer Science and Business Media B.V., 2019.

HIGGINBOTHAM, L. et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease. SCIENCE ADVANCES, [s. l.], v. 6, n. 43, 2020.

HORT, J. et al. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. EUROPEAN JOURNAL OF NEUROLOGY, [s. l.], v. 17, n. 1, p. 90–96, 2010.

HOWARD, S. C. et al. Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, [s. l.], v. 288, n. 16, p. 2001–2007, 2002.

HOWELL, J. C. et al. Race modifies the relationship between cognition and Alzheimer’s disease cerebrospinal fluid biomarkers. ALZHEIMERS RESEARCH & THERAPY, [s. l.], v. 9, 2017.

HU, W. T. et al. Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease. Acta Neuropathologica, [s. l.], v. 120, n. 3, p. 385–399, 2010.

HUANG, J. et al. Inflammation-related plasma and CSF biomarkers for sclerosis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, [s. l.], v. 117, n. 23, p. 12952–12960, 2020.

IRWIN, D. J.; TROJANOWSKI, J. Q.; GROSSMAN, M. Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer’s disease. FRONTIERS IN AGING NEUROSCIENCE, [s. l.], v. 5, 2013.

JABBARI, E. et al. Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA NEUROLOGY, [s. l.], v. 77, n. 3, p. 377–387, 2020.

JANELIDZE, S. et al. Plasma beta-amyloid in Alzheimer’s disease and vascular disease. SCIENTIFIC REPORTS, [s. l.], v. 6, 2016.

JEROMIN, A.; BOWSER, R. Biomarkers in Neurodegenerative Diseases. Em: [S. l.: s. n.], 2017. p. 491–528.

JESSE, S. et al. Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. JOURNAL OF NEUROLOGY, [s. l.], v. 258, n. 6, p. 1034–1041, 2011.

JOHANSSON, P. et al. Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Diagnostic Performance in a Homogeneous Mono-Center Population. JOURNAL OF ALZHEIMERS DISEASE, [s. l.], v. 24, n. 3, p. 537–546, 2011.

JOHNSON, E. C. B. et al. Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nature Medicine, [s. l.], v. 26, n. 5, p. 769–780, 2020.

JULIÁN-JIMÉNEZ, A.; MORALES-CASADO, M. I. Utilidad de las determinaciones analíticas en sangre y líquido cefalorraquídeo para predecir meningitis bacterianas en el servicio de urgencias. Neurología, [s. l.], v. 34, n. 2, p. 105–113, 2019.

KAROBARI, M. I. et al. Endodontic Microbiology: A Bibliometric Analysis of the Top 50 Classics. [S. l.]: Hindawi Limited, 2021.

KESTER, M. I. et al. Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. JAMA NEUROLOGY, [s. l.], v. 71, n. 7, p. 855–862, 2014.

KRASNIANSKI, A. et al. Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease. ARCHIVES OF NEUROLOGY, [s. l.], v. 63, n. 6, p. 876–880, 2006.

LAUTNER, R. et al. Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry, [s. l.], v. 71, n. 10, p. 1183, 2014.

LEEN, W. G. et al. Cerebrospinal Fluid Analysis in the Workup of GLUT1 Deficiency Syndrome A Systematic Review. JAMA NEUROLOGY, [s. l.], v. 70, n. 11, p. 1440–1444, 2013.

LEHMANN, S. et al. Impact of harmonization of collection tubes on Alzheimer’s disease diagnosis. ALZHEIMERS & DEMENTIA, [s. l.], v. 10, n. 5, p. S390-+, 2014.

LEI, C. et al. A Bibliometric Analysis of the Top 50 Most Influential Articles on External Ventricular Drains. World Neurosurgery, [s. l.], v. 172, p. 35–42, 2023.

LEWCZUK, P. et al. Biomarkers of Alzheimer’s disease and mild cognitive impairment: A current perspective. Advances in Medical Sciences, [s. l.], v. 60, n. 1, p. 76–82, 2015.

LISTA, S. et al. CSF Aβ1‐42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer’s disease. Alzheimer’s & Dementia, [s. l.], v. 10, n. 3, p. 381–392, 2014.

LLORENS, F. et al. Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia. ALZHEIMERS & DEMENTIA, [s. l.], v. 12, n. 5, p. 577–589, 2016.

LO SASSO, B. et al. Cerebrospinal Fluid Analysis in Multiple Sclerosis Diagnosis: An Update. Medicina, [s. l.], v. 55, n. 6, p. 245, 2019.

LOTANKAR, S.; PRABHAVALKAR, K. S.; BHATT, L. K. Biomarkers for Parkinson’s Disease: Recent Advancement. NEUROSCIENCE BULLETIN, [s. l.], v. 33, n. 5, p. 585–597, 2017.

MACAULAY, N.; KEEP, R. F.; ZEUTHEN, T. Cerebrospinal fluid production by the choroid plexus: a century of barrier research revisited. [S. l.]: BioMed Central Ltd, 2022.

MAGDALINOU, N. K. et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, [s. l.], v. 86, n. 11, p. 1240–1247, 2015.

MAJBOUR, N. K. et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease. MOLECULAR NEURODEGENERATION, [s. l.], v. 11, 2016.

MATTILA, K. M. et al. Altered blood-brain-barrier function in Alzheimer’s disease? Acta Neurologica Scandinavica, [s. l.], v. 89, n. 3, p. 192–198, 2009.

MATUTE-BLANCH, C. et al. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. BRAIN, [s. l.], v. 141, 2018.

MCLEAN, B. N.; MILLER, D.; THOMPSON, E. J. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behcet’s disease involving the nervous system. Journal of Neurology, Neurosurgery & Psychiatry, [s. l.], v. 58, n. 5, p. 548–554, 1995.

MELAH, K. E. et al. Cerebrospinal Fluid Markers of Alzheimer’s Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer’s Disease. JOURNAL OF ALZHEIMERS DISEASE, [s. l.], v. 50, n. 3, p. 873–886, 2016.

MONJAS-CÁNOVAS, I. et al. Top-cited articles in cerebrospinal fluid leak (rhinorrhea and otorrhea) (1945–2018). Brazilian Journal of Otorhinolaryngology, [s. l.], v. 87, n. 5, p. 557–571, 2021.

MORIARTY, A. T. et al. Immunophenotyping of cytologic specimens by flow cytometry. Diagnostic Cytopathology, [s. l.], v. 9, n. 3, p. 252–258, 1993.

MOYA-ALVARADO, G. et al. Neurodegeneration and Alzheimer’s disease (AD). What Can Proteomics Tell Us About the Alzheimer’s Brain? MOLECULAR & CELLULAR PROTEOMICS, [s. l.], v. 15, n. 2, p. 409–425, 2016.

MULDER, C. et al. Amyloid-beta(1-42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease. CLINICAL CHEMISTRY, [s. l.], v. 56, n. 2, p. 248–253, 2010.

NEGRINI, B.; KELLEHER, K. J.; WALD, E. R. Cerebrospinal fluid findings in aseptic versus bacterial meningitis. PEDIATRICS, [s. l.], v. 105, n. 2, p. 316–319, 2000.

NHO, K. et al. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. JAMA Network Open, [s. l.], v. 2, n. 7, p. e197978, 2019.

NILSELID, A. M. et al. Clusterin in cerebrospinal fluid: Analysis of carbohydrates and quantification of native and glycosylated forms. NEUROCHEMISTRY INTERNATIONAL, [s. l.], v. 48, n. 8, p. 718–728, 2006.

NISHIMOTO, Y. et al. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. JOURNAL OF NEUROIMMUNOLOGY, [s. l.], v. 148, n. 1–2, p. 200–205, 2004.

OHRFELT, A. et al. The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease. ALZHEIMERS RESEARCH & THERAPY, [s. l.], v. 8, 2016.

OKONKWO, O. C. Cerebrospinal Fluid Abnormalities and Rate of Decline in Everyday Function Across the Dementia Spectrum. Archives of Neurology, [s. l.], v. 67, n. 6, p. 688, 2010.

ORLOVSKA-WAAST, S. et al. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. MOLECULAR PSYCHIATRY, [s. l.], v. 24, n. 6, p. 869–887, 2019.

OSCHMANN, P. et al. Stages and syndromes of neuroborreliosis. JOURNAL OF NEUROLOGY, [s. l.], v. 245, n. 5, p. 262–272, 1998.

PARNETTI, L. et al. Cerebrospinal fluid biomarkers in Parkinson disease. NATURE REVIEWS NEUROLOGY, [s. l.], v. 9, n. 3, p. 131–140, 2013.

PARNETTI, L. et al. Cerebrospinal Fluid Biomarkers in Parkinson’s Disease with Dementia and Dementia with Lewy Bodies. BIOLOGICAL PSYCHIATRY, [s. l.], v. 64, n. 10, p. 850–855, 2008.

PARNETTI, L. et al. Cerebrospinal Fluid Tau/alpha-Synuclein Ratio in Parkinson’s Disease and Degenerative Dementias. MOVEMENT DISORDERS, [s. l.], v. 26, n. 8, p. 1428–1435, 2011.

PARNETTI, L. et al. CSF and blood biomarkers for Parkinson’s disease. The Lancet Neurology, [s. l.], v. 18, n. 6, p. 573–586, 2019.

PERANI, D. et al. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, [s. l.], v. 43, n. 3, p. 499–508, 2016.

PETZOLD, A. Intrathecal oligoclonal IgG synthesis in multiple sclerosis. JOURNAL OF NEUROIMMUNOLOGY, [s. l.], v. 262, n. 1–2, p. 1–10, 2013.

PIRZADA, N. A.; ALI, I. I.; DAFER, R. M. Fluorouracil-induced neurotoxicity. ANNALS OF PHARMACOTHERAPY, [s. l.], v. 34, n. 1, p. 35–38, 2000.

PRASHANTH, R. et al. High-Accuracy Detection of Early Parkinson’s Disease through Multimodal Features and Machine Learning. INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, [s. l.], v. 90, p. 13–21, 2016.

RAHIMI, J.; WOEHRER, A. Overview of cerebrospinal fluid cytology. Em: HANDBOOK OF CLINICAL NEUROLOGY. [S. l.]: Elsevier B.V., 2018. v. 145, p. 563–571.

RAMOS-RINCON, J.-M. et al. Research in Cerebrospinal Fluid Leak (Rhinorrhea and Otorrhea): A Bibliometric Analysis From 1945 to 2018. Cureus, [s. l.], 2022.

RIEDL, L. et al. Frontotemporal lobar degeneration: current perspectives. NEUROPSYCHIATRIC DISEASE AND TREATMENT, [s. l.], v. 10, p. 297–310, 2014.

RUETSCHI, U. et al. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. EXPERIMENTAL NEUROLOGY, [s. l.], v. 196, n. 2, p. 273–281, 2005.

SAMANCI, Y.; SAMANCI, B.; SAHIN, E. Bibliometric analysis of the top-cited articles on idiopathic intracranial hypertension. Neurology India, [s. l.], v. 67, n. 1, p. 78, 2019.

SCHELTENS, N. M. E. et al. The identification of cognitive subtypes in Alzheimer’s disease dementia using latent class analysis. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, [s. l.], v. 87, n. 3, p. 235–243, 2016.

SCHINDLER, S. E. et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. ALZHEIMERS & DEMENTIA, [s. l.], v. 14, n. 11, p. 1460–1469, 2018.

SCHOONENBOOM, N. S. M. et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology, [s. l.], v. 78, n. 1, p. 47–54, 2012.

SENGUPTA, N. et al. Analysis of 100 most cited articles on forensic odontology. The Saudi Dental Journal, [s. l.], v. 32, n. 7, p. 321–329, 2020.

SHAW, L. M. et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathologica, [s. l.], v. 121, n. 5, p. 597–609, 2011.

SHI, M. et al. Cerebrospinal Fluid Biomarkers for Parkinson Disease Diagnosis and Progression. ANNALS OF NEUROLOGY, [s. l.], v. 69, n. 3, p. 570–580, 2011.

SIMON, L. et al. Bing-Neel syndrome, a rare complication of Waldenstrom macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO). HAEMATOLOGICA, [s. l.], v. 100, n. 12, p. 1587–1594, 2015.

SIMONSEN, A. H. et al. The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. BIOMARKERS IN MEDICINE, [s. l.], v. 10, n. 1, p. 19–34, 2016.

SINGH, A. K. et al. Paradoxical reaction in tuberculous meningitis: presentation, predictors and impact on prognosis. BMC INFECTIOUS DISEASES, [s. l.], v. 16, 2016.

SKIEST, D. J. Focal neurological disease in patients with acquired immunodeficiency syndrome. CLINICAL INFECTIOUS DISEASES, [s. l.], v. 34, n. 1, p. 103–115, 2002.

SKILLBACK, T. et al. Cerebrospinal fluid tau and amyloid-beta(1-42) in patients with dementia. BRAIN, [s. l.], v. 138, p. 2716–2731, 2015.

SNIDER, B. J. et al. Cerebrospinal Fluid Biomarkers and Rate of Cognitive Decline in Very Mild Dementia of the Alzheimer Type. ARCHIVES OF NEUROLOGY, [s. l.], v. 66, n. 5, p. 638–645, 2009.

SONNEVILLE, R. et al. Post-infectious encephalitis in adults: Diagnosis and management. JOURNAL OF INFECTION, [s. l.], v. 58, n. 5, p. 321–328, 2009.

STOECK, K. et al. Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. BRAIN, [s. l.], v. 135, p. 3051–3061, 2012.

STOMRUD, E. et al. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, [s. l.], v. 24, n. 2, p. 118–124, 2007.

STRUYFS, H. et al. Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-beta Isoforms for Early and Differential Dementia Diagnosis. JOURNAL OF ALZHEIMERS DISEASE, [s. l.], v. 45, n. 3, p. 813–822, 2015.

SUTPHEN, C. L. et al. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer’s disease. Alzheimer’s & Dementia, [s. l.], v. 14, n. 7, p. 869–879, 2018.

TAN, C. C.; YU, J. T.; TAN, L. Biomarkers for Preclinical Alzheimer’s Disease. JOURNAL OF ALZHEIMERS DISEASE, [s. l.], v. 42, n. 4, p. 1051–1069, 2014.

TARAWNEH, R. et al. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. JAMA NEUROLOGY, [s. l.], v. 73, n. 5, p. 561–571, 2016.

TEDDER, D. G. Herpes Simplex Virus Infection as a Cause of Benign Recurrent Lymphocytic Meningitis. Annals of Internal Medicine, [s. l.], v. 121, n. 5, p. 334, 1994.

THORSELL, A. et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer’s disease. Brain Research, [s. l.], v. 1362, p. 13–22, 2010.

TOLBOOM, N. et al. Relationship of Cerebrospinal Fluid Markers to C-11-PiB and F-18-FDDNP Binding. JOURNAL OF NUCLEAR MEDICINE, [s. l.], v. 50, n. 9, p. 1464–1470, 2009.

TOSUN, D. et al. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiology of Aging, [s. l.], v. 31, n. 8, p. 1340–1354, 2010.

TUMANI, H.; HUSS, A.; BACHHUBER, F. The cerebrospinal fluid and barriers – anatomic and physiologic considerations. Em: HANDBOOK OF CLINICAL NEUROLOGY. [S. l.]: Elsevier B.V., 2017. v. 146, p. 3–20.

VAN ECK, N. J.; WALTMAN, L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics, [s. l.], v. 84, n. 2, p. 523–538, 2010.

VOS, S. J. B. et al. Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice. PLOS ONE, [s. l.], v. 9, n. 6, 2014.

WALLIN, A. K. et al. CSF biomarkers predict a more malignant outcome in Alzheimer disease. NEUROLOGY, [s. l.], v. 74, n. 19, p. 1531–1537, 2010.

WANG, Y. et al. Surface-based TBM boosts power to detect disease effects on the brain: An N=804 ADNI study. NeuroImage, [s. l.], v. 56, n. 4, p. 1993–2010, 2011.

WICHMANN, T. O.; DAMKIER, H. H.; PEDERSEN, M. A Brief Overview of the Cerebrospinal Fluid System and Its Implications for Brain and Spinal Cord Diseases. [S. l.]: Frontiers Media S.A., 2022.

WOLFSGRUBER, S. et al. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. JOURNAL OF ALZHEIMERS DISEASE, [s. l.], v. 58, n. 3, p. 939–950, 2017.

WU, J. et al. Knowledge mapping of syringomyelia from 2003 to 2022: A bibliometric analysis. [S. l.]: Churchill Livingstone, 2023.

ZHANG, M. et al. Required Reading: The Most Impactful Articles in Endoscopic Endonasal Skull Base Surgery. World Neurosurgery, [s. l.], v. 92, p. 499-512.e2, 2016.

ZWAN, M. et al. Concordance Between Cerebrospinal Fluid Biomarkers and [C-11] PIB PET in a Memory Clinic Cohort. JOURNAL OF ALZHEIMERS DISEASE, [s. l.], v. 41, n. 3, p. 801–807, 2014.




Como Citar

Figueiredo Filho, L. C., Aranha, M. F. de A. C., Cabeça, R. A. S., Massoud, R. O., Cohen, S. B., Fernandes, L. de M. P., de Oliveira, R. de C. S., & Cohen, P. B. (2023). CEREBROSPINAL FLUID EVALUATION AS A DIAGNOSIS AND PROGNOSIS TOOL: A BIBLIOMETRIC ANALYSIS OF THE 100 MOST CITED ARTICLES. Arquivos De Ciências Da Saúde Da UNIPAR, 27(10), 5624–5659. https://doi.org/10.25110/arqsaude.v27i10.2023-012